Condition: Tuberculosis · Multidrug Resistant Tuberculosis · Sponsor: Assistance Publique - Hôpitaux de Paris
The objective of this work is to measure the early bactericidal activity of tedizolid, to compare it with the bactericidal activity of linezolid (reference molecule for the treatment of multidrug-resistant tuberculosis) and with that of standard quadruple therapy (reference treatment of drug susceptible tuberculosis).
This description comes directly from the study's public registry record.
Nicolas VEZIRIS, PU-PH · 01 49 28 30 41 · nicolas.veziris@aphp.fr
Ruxandra CALIN, MD · 01 56 01 74 12 · ruxandra.calin@aphp.fr
Always discuss trial participation with your own doctor first.
| Bacteriology department- Hôpital Saint-Antoine | Paris, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05534750